Monday, November 4, 2024

Friends of Cancer Research: Variability of HRD Testing; Dx Meeting on 2/5/2025

Friends of Cancer Research (FoCR) has sponsored a new publication on variability among different tests to measure HRD - homologous recombination deficiency.  This tumor tests helps select PARP inhibitors in ovarian cancer.

Find the press release here

   Find the article, Andrews et al., here.   

       Register for a half-day meeting in DC or online, on February 5, 2025 - here.

The paper focuses on variability per se.  There wasn't a comparison of accuracy against a gold standard, because, there wasn't an agreed-upon gold standard.